With a growing portfolio in an attractive rare-disease niche—and acceleration of profit growth beginning in 2022—BioMarin could be an acquisition target for pharmaceutical firms with pipelines to fill ...

MS experts are recommending updates to the 2017 McDonald diagnostic criteria that aim to make diagnosis easier, faster and more accurate.

SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today ...

Rachel Sha has had a colorful career not without its challenges, but she urges women in the science industry to have ...

Marc Moodley has worked at Sanofi since 2018 and is the new medical head, UK and Ireland for the company’s Genzyme unit. A pharmaceutical physician with experience in R&D, global medical affairs ...

Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...

FRANKFURT (Reuters) - Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a ...

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...

We want to build a healthier, more resilient world. We turn the impossible into the possible by discovering, developing, and delivering medicines and vaccines for millions of people around the world.